Inflation, Biosimilars, And The Wizard Of Oz: An Interview With Teva’s Christine Baeder

The new chair of the US generics association talks to the Pink Sheet about how to make sure that policymakers don’t take the industry for granted.

tornado
Bad news for antibiotics? • Source: Shutterstock

Christine Baeder, Teva Pharmaceutical Industries Ltd.’s senior vice president and chief operating officer for US generics, was just elected chair of the Association of Accessible Medicines’ board of directors, giving her a commanding view of some of the most momentous events for the generic industry in the coming year, including the early implementation of the Inflation Reduction Act’s drug pricing provisions and the launch of biosimilars for the biggest Rx product in the world, Humira.

The Pink Sheet caught up with Baeder at the sidelines of the AAM’s annual meeting in Orlando on 14 February....

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics